Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
166 hedge funds and large institutions have $1.63B invested in Genomic Health, Inc. in 2018 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 52 increasing their positions, 50 reducing their positions, and 10 closing their positions.
320% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 10
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
94% more call options, than puts
Call options by funds: $1.77M | Put options by funds: $912K
63% more capital invested
Capital invested by funds: $1B → $1.63B (+$630M)
24% more funds holding
Funds holding: 134 → 166 (+32)
4% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$31.8M |
| 2 |
Renaissance Technologies
New York
|
+$8.82M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$8.43M |
| 4 |
Goldman Sachs
New York
|
+$7.67M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$39M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$7.22M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$5.2M |
| 5 |
Charles Schwab
San Francisco,
California
|
-$3.85M |
GHDX Hedge Fund Activity: Q2 2018 in Review
166 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q2 2018, worth a combined $1.63B — up 63% from $1B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new GHDX positions and 10 closed out — a net gain of 32 holders — while 52 added to existing stakes and 50 trimmed.
The largest buyer was Millennium Management, adding an estimated $31.8M. The largest seller was Ameriprise, cutting an estimated $39M.
- 166 institutional investors held Genomic Health, Inc. (GHDX) as of Q2 2018, up from 134 in Q1 2018.
- Funds reported $1.63B of Genomic Health, Inc. stock for Q2 2018, up 63% quarter-over-quarter.
- 42 funds opened new Genomic Health, Inc. positions in Q2 2018 and 10 closed out, a net change of +32 holders.
- The largest Genomic Health, Inc. buyer in Q2 2018 was Millennium Management, an estimated $31.8M added.
- The largest Genomic Health, Inc. seller in Q2 2018 was Ameriprise, an estimated $39M sold.
Based on aggregated 13F filings for Q2 2018.